Any prescription of a sodium-glucose co-transporter-2 inhibitor (SGLT2i aka gliflozin). Code set created by searching for each named gliflozin (canagliflozin/vokanamet/invokana/dapagliflozin/xigduo/forxiga/qtern/empagliflozin/synjardy/jardiance/glyxambi/ertugliflozin/steglatro/ipragliflozin/luseogliflozin/remogliflozin/sergliflozin/sotagliflozin/tofogliflozin) in the SNOMED browser.
By examining the prevalence of codes (number of patients with the code in their record) broken down by clinical system, we can attempt to validate the clinical code sets and the reporting of the conditions. Here is a log for this code set. The prevalence range 1.25% - 1.25% for EMIS and Vision suggests that this code set is well defined. The figure of 0.90% for TPP is lower than expected, but TPP have the smallest patient population so a degree of variability is to be expected.
Update 2023-10-27: Prevalence is now in the range 2.07% - 2.19% which suggests this code set is now more consistent.
Update 2024-03-06: Prevalence is now in the range 2.2% - 2.4%.
| Date | Practice system | Population | Patients from ID | Patient from code |
|---|---|---|---|---|
| 2021-08-26 | EMIS | 2623304 | 32817 (1.25%) | 32817 (1.25%) |
| 2021-08-26 | TPP | 211610 | 1899 (0.90%) | 1899 (0.90%) |
| 2021-08-26 | Vision | 337028 | 4211 (1.25%) | 4211 (1.25%) |
| 2023-10-27 | EMIS | 2472595 | 51233 (2.07%) | 51239 (2.07%) |
| 2023-10-27 | TPP | 200603 | 4387 (2.19%) | 4387 (2.19%) |
| 2023-10-27 | Vision | 332447 | 6960 (2.09%) | 6961 (2.09%) |
| 2024-03-06 | EMIS | 2525894 | 56629 (2.24%) | 56634 (2.24%) |
| 2024-03-06 | TPP | 201753 | 4879 (2.42%) | 4880 (2.42%) |
| 2024-03-06 | Vision | 335117 | 7604 (2.27%) | 7605 (2.27%) |
- Find_missing_codes last run 2024-03-06